Video

Dr. Tauer on the Expansion of Subtyping in Breast Cancer

Kurt W. Tauer, MD, FACP, discusses the expansion of subtyping in breast cancer.

Kurt W. Tauer, MD, FACP, associate professor, Department of Hematology/Oncology, the University of Tennessee Health Science Center, and senior partner, chief of staff, West Cancer Center, discusses the expansion of subtyping in breast cancer.

There is still much work to be done with creating subtypes of breast cancer and finding treatments that are effective within those groups, explains Tauer. The recent approval of alpelisib (Piqray) for patients with PIK3CA-mutated breast cancer demonstrates the effectiveness of personalized medicine in this field.

To develop more subtypes of breast cancer in which researchers are looking for treatment, Tauer recommends performing more next-generation sequencing. Personalized medicine, currently being developed in breast cancer with the emergence of estrogen receptor, progesterone receptor, and HER2 data, is positive for the future of treatment, concludes Tauer.

Newsletter

Stay up to date on the most recent and practice-changing oncology data

Latest CME

View All
Tumor Board: Expert Insights on Managing Classical 𝘌𝘎𝘍𝘙 Mutations, 𝘌𝘎𝘍𝘙 Exon 20 Insertions, and Atypical 𝘌𝘎𝘍𝘙 Mutations in Metastatic NSCLC
Video

Tumor Board: Expert Insights on Managing Classical 𝘌𝘎𝘍𝘙 Mutations, 𝘌𝘎𝘍𝘙 Exon 20 Insertions, and Atypical 𝘌𝘎𝘍𝘙 Mutations in Metastatic NSCLC

Jun 6th 2025 - Jul 12th 2025

online-activity
Medical Crossfire®: Expert Perspectives on Targeting c-Met Overexpression and 𝘔𝘌𝘛 Genomic Alterations in NSCLC – Unveiling the Complexities of 𝘔𝘌𝘛 Dysregulation
Video

Medical Crossfire®: Expert Perspectives on Targeting c-Met Overexpression and 𝘔𝘌𝘛 Genomic Alterations in NSCLC – Unveiling the Complexities of 𝘔𝘌𝘛 Dysregulation

Jun 6th 2025 - Jul 12th 2025

online-activity
Evolving Treatment Strategies in Pancreatic Cancer: Current Standards, Emerging Targets, and the Role of Molecular Testing
Video

Evolving Treatment Strategies in Pancreatic Cancer: Current Standards, Emerging Targets, and the Role of Molecular Testing

Jun 5th 2025 - Jul 12th 2025

online-activity